So the end result is most likely patients will continue to need P on a limited basis for the rest of their lives? If so, good news for IPIX/BP as to revenues and if cost not exorbitant I am sure patients / insurers won't be taken aback as long as it cures the day to day symptoms.
(2)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links